BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib

Share:

Listens: 0

AudioMedica.com

Science


BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled double-blind phase three SOLO1 study of women with newly diagnosed ovarian cancer who had BRCA1/2 mutations and …Kathleen Moore OLAPARIB FIRST LINE IN OVAIAN CANCER